LG CNS invests in CHA Biotech to fast-track AI-powered digital health care

LG CNS is accelerating its digital health care business in partnership with CHA Biomedical Group, making a 10 billion won ($6.8 million) equity investment in its affiliate CHA Biotech. The company said Thursday that it signed a strategic partnership agreement with CHA Biotech a day earlier to carry out the investment and collaborate on artificial intelligence (AI) transformation (AX) and digital transformation (DX) initiatives for the development of AI-powered digital health care services. CHA Biomedical Group is a comprehensive bio and health care company spanning hospitals, pharmaceuticals, biotechnology research and medical services with several affiliates, including CHA Biotech, CHA Meditech, CMG Pharmaceutical and CHA Vaccine Institute. Through this investment, LG CNS and CHA Biomedical Group plan to establish a regular joint consultative body and carry out major AX and DX projects. “Through our partnership with CHA Biomedical Group, we aim to strengthen our competitiveness in digital health care platforms,” an LG CNS official said. “We will position ourselves as a leading tecWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times